We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-56.03%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$2.12M
AUM Growth
-$152M
(-99%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-7,058.09%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
21
New
–
Increased
–
Reduced
–
Closed
20
Top Buys
No buys this quarter
Top Sells
| 1 |
Viatris
VTRS
|
+$6.66M |
| 2 |
Becton Dickinson
BDX
|
+$6.46M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$5.72M |
| 4 |
McKesson
MCK
|
+$4.78M |
| 5 |
Collegium Pharmaceutical
COLL
|
+$4.13M |
Sector Composition
| 1 | Healthcare | 100% |
No holdings matched the selected filter criteria.
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, Tamarack Advisers held 21 positions worth $2.12M, down 99% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Tamarack Advisers withdrew a net $150M in Q4 2023, closing 20 positions. Its most notable exit was Viatris, an estimated $6.66M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 32% a quarter earlier.
- Tamarack Advisers fully exited Viatris in Q4 2023, selling an estimated $6.66M.
- Tamarack Advisers's ten largest holdings make up 100% of its $2.12M portfolio in Q4 2023.
- Tamarack Advisers opened 0 new positions and closed 20 in Q4 2023.
- Tamarack Advisers's portfolio value fell 99% quarter-over-quarter to $2.12M.
Based on Tamarack Advisers's 13F filing for Q4 2023, filed 9 Feb 2024.